View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML
HHS/FDA RIN: 0910-AI82 Publication ID: Spring 2025 
Title: Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products 
Abstract:

The rule will establish and require standardized testing methods for detecting and identifying asbestos in talc-containing cosmetic products. 

 
Agency: Department of Health and Human Services(HHS)  Priority: Other Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Final Rule Stage 
Major: Undetermined  Unfunded Mandates: No 
EO 14192 Designation: Regulatory 
CFR Citation: 21 CFR Part 730     (To search for a specific CFR, visit the Code of Federal Regulations.)
Legal Authority: sec. 3505 of the Modernization of Cosmetics Regulation Act of 2022   
Legal Deadline:
Action Source Description Date
Final  Statutory    09/26/2025 

Overall Description of Deadline: Under section 3505 of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), the Secretary of Health and Human Services shall promulgate proposed regulations to establish and require standardized testing methods for detecting and identifying asbestos in talc-containing cosmetic products. The proposed rule was issued on December 27, 2024. The final rule is to issue not later than 180 days after the date on which the comment period closes.

Timetable:
Action Date FR Cite
NPRM  12/27/2024  89 FR 105490   
NPRM Comment Period End  03/27/2025 
Final Rule  03/00/2026 
Regulatory Flexibility Analysis Required: Undetermined  Government Levels Affected: None 
Federalism: Undetermined 
Included in the Regulatory Plan: No 
International Impacts: This regulatory action will be likely to have international trade and investment effects, or otherwise be of international interest.
RIN Data Printed in the FR: No 
Agency Contact:
Iris Chen
Regulatory Counsel
Department of Health and Human Services
Food and Drug Administration
Office of the Chief Scientist, 10903 New Hampshire Avenue,
Silver Spring, MD 20993
Phone:240 402-3613
Email: questionsaboutmocra@fda.hhs.gov